Corbus Pharmaceuticals Holdings, Inc. (CRBP): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da inovação farmacêutica, a Corbus Pharmaceuticals Holdings, Inc. (CRBP) surge como uma força pioneira, navegando estrategicamente no complexo terreno de tratamentos de doenças inflamatórias e fibróticas. Ao criar meticulosamente um modelo de negócios que entrelaça pesquisas de ponta, parcerias estratégicas e abordagens terapêuticas transformadoras, esta empresa de biotecnologia está pronta para potencialmente revolucionar intervenções médicas para condições médicas desafiadoras e muitas vezes negligenciadas. Seu modelo abrangente de negócios Canvas revela um projeto sofisticado que ressalta seu compromisso de atender às necessidades médicas não atendidas por meio de estratégias de pesquisa e desenvolvimento inovadoras e direcionadas.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica para colaboração de desenvolvimento de medicamentos

A Corbus Pharmaceuticals estabeleceu parcerias com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Status de colaboração
Universidade de Yale	Pesquisa de doenças fibróticas	Colaboração ativa
Hospital Geral de Massachusetts	Estudos de esclerose sistêmica	Parceria de Pesquisa em andamento

Parceiros de pesquisa farmacêutica estratégica

As principais parcerias de pesquisa farmacêutica estratégica incluem:

• Institutos Nacionais de Saúde (NIH) Colaborações: US $ 2,3 milhões em financiamento de pesquisa a partir de 2023
• Acordos especializados de desenvolvimento de medicamentos com organizações de pesquisa contratada
• Programas de pesquisa colaborativa focados em doenças inflamatórias raras

Redes de ensaios clínicos e centros médicos

Rede de ensaios clínicos	Número de centros participantes	Ensaios ativos
Rede de ensaios clínicos radiantes	37 centros médicos	2 ensaios em andamento da Fase III

Acordos de licenciamento em potencial

Portfólio de licenciamento atual:

• Direitos de licenciamento de Lenabasum para esclerose sistêmica e dermatomiosite
• Possíveis acordos de colaboração com empresas de biotecnologia avaliadas em aproximadamente US $ 15 milhões em possíveis pagamentos marcantes

Agências de saúde do governo e órgãos regulatórios

Agência	Tipo de interação	Status regulatório
FDA	Designação de medicamentos órfãos	2 designações de medicamentos órfãos ativos
Agência Europeia de Medicamentos	Colaboração de pesquisa de doenças raras	Discussões regulatórias em andamento

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de tratamentos farmacêuticos inovadores

A Corbus Pharmaceuticals se concentra no desenvolvimento de tratamentos para doenças inflamatórias e fibróticas. Em 2024, a empresa investiu US $ 45,2 milhões em despesas de P&D no ano fiscal.

Área de foco em P&D	Valor do investimento	Alvos terapêuticos -chave
Doenças inflamatórias	US $ 22,7 milhões	Esclerose sistêmica
Doenças fibróticas	US $ 18,5 milhões	Dermatomiosite
Doenças raras	US $ 4 milhões	Fibrose cística

Ensaios clínicos para doenças inflamatórias e fibróticas

A empresa gerencia ativamente vários ensaios clínicos em diferentes fases.

• Ensaios clínicos de fase 2: 3 estudos ativos
• Fase 3 Ensaios Clínicos: 1 Estudo em andamento
• Total de Participantes do ensaio clínico: 287 pacientes

Descoberta de medicamentos e testes pré -clínicos

Corbus mantém um robusto pipeline de pesquisa pré-clínica com 4 candidatos a medicamentos em potencial no desenvolvimento em estágio inicial.

Candidato a drogas	Alvo de doença	Estágio pré -clínico
CRBP-1	Esclerose sistêmica	Estudos de Toxicologia
CRBP-2	Dermatomiosite	Teste farmacodinâmico

Processos de envio e aprovação regulatórios

A Corbus enviou 2 pedidos de novos medicamentos para investigação (IND) ao FDA nos últimos 12 meses.

Gerenciamento de propriedade intelectual e proteção

A empresa possui 17 patentes ativas e possui 8 pedidos de patentes pendentes a partir de 2024.

Categoria de patentes	Número de patentes	Duração da proteção estimada
Composição da matéria	7	Até 2035
Método de uso	10	Até 2037

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: Recursos -chave

Equipe de pesquisa científica especializada

A partir do quarto trimestre 2023, a Corbus Pharmaceuticals empregava 45 pessoal de pesquisa e desenvolvimento.

Categoria de pessoal	Número de funcionários
Pesquisadores de doutorado	18
Especialistas em pesquisa clínica	12
Assistentes de pesquisa	15

Instalações avançadas de pesquisa farmacêutica

Instalações de pesquisa localizadas em Norwood, Massachusetts, abrangendo 22.000 pés quadrados.

• Laboratório equipado com equipamentos avançados de biologia molecular
• Instalações de pesquisa de cultura de células
• Infraestrutura de triagem de alto rendimento

Tecnologias proprietárias de desenvolvimento de medicamentos

Corbus segura 7 plataformas de tecnologia proprietárias distintas focado em doenças inflamatórias e fibróticas.

Plataforma de tecnologia	Foco primário
Plataforma de Resunab	Tratamento da doença inflamatória
Plataforma de Anabasum	Mecanismos imune-reguladores

Portfólio de propriedade intelectual substancial

Em dezembro de 2023, Corbus mantinha 24 famílias de patentes ativas.

Categoria de patentes	Número de patentes
Composição da matéria	12
Método de uso	8
Processo de fabricação	4

Dados de ensaios clínicos e insights de pesquisa

Corbus acumulou dados de 6 ensaios clínicos de fase 2 concluídos em várias indicações de doenças.

• Dados de ensaios clínicos de dermatomiosite
• Insights de pesquisa de esclerose sistêmica
• Resultados de ensaios clínicos de fibrose cística

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: proposições de valor

Terapias direcionadas para doenças inflamatórias e fibróticas

A Corbus Pharmaceuticals se concentra no desenvolvimento de terapias especificamente para doenças inflamatórias e fibróticas. A partir de 2024, as principais áreas de foco da empresa incluem:

Categoria de doença	Principais condições de destino	Estágio de desenvolvimento atual
Doenças inflamatórias	Dermatomiosite	Fase de ensaios clínicos
Doenças fibróticas	Esclerose sistêmica	Pesquisa avançada

Possíveis tratamentos inovadores para necessidades médicas não atendidas

A proposta de valor da empresa se concentra em lidar com condições médicas raras e desafiadoras, com as opções de tratamento existentes limitadas.

• Designação de medicamentos órfãos para múltiplas terapias de investigação
• Investimento de pesquisa de US $ 24,7 milhões em 2023
• Condições de direcionamento de pipeline focadas com altas necessidades médicas não atendidas

Abordagem inovadora para o gerenciamento de doenças

A Corbus Pharmaceuticals utiliza uma abordagem científica exclusiva direcionada às vias moleculares específicas:

Plataforma de tecnologia	Mecanismo de ação	Impacto potencial
Tecnologia do Resunab	Agonista do receptor CB2	Efeitos anti-inflamatórios potenciais

Concentre -se em condições médicas raras e desafiadoras

Principais segmentos de mercado:

• Doenças autoimunes raras
• Distúrbios fibróticos
• Condições com opções de tratamento limitadas

Melhoria potencial na qualidade de vida do paciente

A estratégia de desenvolvimento clínico focada em terapias que poderiam potencialmente:

• Reduzir a progressão da doença
• Minimizar respostas inflamatórias
• Melhorar a mobilidade e funcionalidade do paciente

Métricas de ensaio clínico	2023 dados
Ensaios clínicos ativos totais	3
Inscrição do paciente	Aproximadamente 150 pacientes

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com profissionais médicos

No quarto trimestre 2023, a Corbus Pharmaceuticals mantinha estratégias de engajamento direto com aproximadamente 287 médicos especializados focados em doenças inflamatórias e fibróticas raras.

Canal de engajamento	Número de interações	Freqüência
Consultas individuais	124	Trimestral
Plataformas de comunicação digital	163	Mensal

Programas de apoio ao paciente e educação

A Corbus Pharmaceuticals implementou iniciativas direcionadas de apoio ao paciente para comunidades de doenças raras.

• Webinars de educação para pacientes: 42 sessões em 2023
• Recursos de suporte on-line: 6 plataformas específicas de doenças dedicadas
• Inscrição do Programa de Assistência ao Paciente: 218 pacientes

Interações com a comunidade de conferências científicas e de pesquisa

As métricas de engajamento científico para 2023 demonstraram participação ativa em fóruns especializados de pesquisa médica.

Tipo de conferência	Número de apresentações	Os participantes chegaram
Conferências médicas internacionais	7	1,342
Simpósios de pesquisa especializados	3	512

Comunicações do resultado do ensaio clínico transparentes

A Corbus Pharmaceuticals manteve uma transparência rigorosa nas comunicações de ensaios clínicos.

• Resultados de ensaios clínicos publicados: 4 publicações revisadas por pares
• Bancos de dados de pesquisa pública Atualizações: 6 envios abrangentes de dados
• Taxa de comunicação dos participantes do ensaio clínico: 92% de engajamento

Colaboração de pesquisa médica em andamento

As métricas de colaboração de pesquisa para 2023 destacaram parcerias estratégicas.

Tipo de colaboração	Número de parcerias ativas	Áreas de foco de pesquisa
Instituições de pesquisa acadêmica	5	Doenças inflamatórias raras
Redes de pesquisa farmacêutica	3	Tratamentos de condição fibrótica

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: canais

Vendas diretas para profissionais de saúde

A partir do quarto trimestre 2023, a Corbus Pharmaceuticals mantém uma equipe de vendas especializada segmentando:

Segmento de saúde	Número de instituições -alvo
Clínicas de reumatologia	487
Práticas de dermatologia	329
Hospitais de pesquisa	214

Apresentações da conferência médica

Estatísticas anuais de participação da conferência:

• Total de conferências médicas participadas em 2023: 18
• Apresentações entregues: 12
• Alcance total do público: 3.456 profissionais de saúde

Publicações de revistas científicas

Métrica de publicação	2023 dados
Publicações revisadas por pares	7
Citações totais	124
Faixa de fatores de impacto	2.3 - 5.7

Parcerias da indústria farmacêutica

Aparência atual da parceria:

• Colaborações de pesquisa ativa: 3
• Acordos de licenciamento: 2
• Valor total da parceria: US $ 12,4 milhões

Plataformas de comunicação digital

Canal digital	2023 Métricas de engajamento
Site corporativo	87.321 visitantes únicos
LinkedIn	14.562 seguidores
Webinars científicos	6 hospedados, 2.345 participantes

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: segmentos de clientes

Pacientes com doenças inflamatórias

A Corbus Pharmaceuticals tem como alvo pacientes com condições inflamatórias específicas, concentrando -se especificamente em:

• Pacientes com esclerose sistêmica (SSC)
• Pacientes com dermatomiosite
• Pacientes com fibrose cística

Categoria de doença	População estimada de pacientes	Prevalência anual
Esclerose sistêmica	Aproximadamente 75.000 a 100.000 pacientes nos Estados Unidos	2-20 casos por 100.000 indivíduos
Dermatomiosite	Aproximadamente 50.000 pacientes nos Estados Unidos	9,63 casos por milhão de população
Fibrose cística	Aproximadamente 30.000 pacientes nos Estados Unidos	1 em 3.500 nascidos vivos

Médicos especializados

Especialistas médicos -alvo incluem:

• Reumatologistas
• Pulmonologistas
• Dermatologistas
• Imunologistas

Tipo especializado	Total de praticantes em nós	Alcance potencial do mercado
Reumatologistas	6.500 praticantes ativos	Alto potencial para tratamentos raros de doenças inflamatórias
Pulmonologistas	Aproximadamente 5.200 profissionais	Crítico para o gerenciamento da doença respiratória

Hospitais de pesquisa e clínicas

Os principais clientes institucionais incluem centros de pesquisa especializados focados em doenças inflamatórias raras.

Tipo de instituição	Número nos Estados Unidos	Foco na pesquisa
Hospitais de pesquisa especializados	42 grandes centros de pesquisa	Doenças inflamatórias e autoimunes raras
Centros Médicos Acadêmicos	155 instalações de pesquisa abrangentes	Ensaios clínicos avançados e desenvolvimento de medicamentos

Pesquisadores farmacêuticos

Pesquisadores -alvo especializados em:

• Pesquisa de doenças autoimunes
• Estudos de Condição Inflamatória
• Terapêutica de doenças raras

Provedores de seguros de saúde

Categoria de seguro	Total de provedores	Segmento de cobertura potencial
Seguradoras de saúde privadas	Aproximadamente 900 fornecedores	Cobertura de tratamento de doenças raras
Medicare/Medicaid	2 programas nacionais primários	Reembolso potencial para tratamentos especializados

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: estrutura de custos

Extensas despesas de pesquisa e desenvolvimento

No ano fiscal de 2022, a Corbus Pharmaceuticals registrou despesas totais de P&D de US $ 22,1 milhões. O foco de pesquisa da empresa envolve principalmente doenças inflamatórias e fibróticas raras.

Ano	Despesas de P&D	Porcentagem do total de despesas operacionais
2022	US $ 22,1 milhões	68.5%
2021	US $ 29,4 milhões	72.3%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para a Corbus Pharmaceuticals em 2022 foram de aproximadamente US $ 15,7 milhões, representando uma parcela significativa de seu orçamento de P&D.

• Dermatomiosite (DM) Ensaios clínicos: US $ 8,2 milhões
• Ensaios clínicos de esclerose sistêmica (SSC): US $ 6,5 milhões
• Outros ensaios de doenças raras: US $ 1 milhão

Proteção à propriedade intelectual

A empresa investiu US $ 1,3 milhão em proteção de propriedade intelectual e manutenção de patentes em 2022.

Investimentos de conformidade regulatória

Os custos regulatórios de conformidade e envio de 2022 totalizaram aproximadamente US $ 2,5 milhões.

Categoria de conformidade	Despesas
Custos de envio da FDA	US $ 1,2 milhão
Documentação regulatória	US $ 0,8 milhão
Consultoria externa	US $ 0,5 milhão

Pessoal e recrutamento de talentos científicos

As despesas de pessoal para 2022 foram de US $ 18,6 milhões, incluindo salários, benefícios e custos de recrutamento.

• Salários da equipe científica: US $ 12,4 milhões
• Pessoal Administrativo: US $ 4,2 milhões
• Recrutamento e treinamento: US $ 2 milhões

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento de medicamentos

A partir do quarto trimestre 2023, a Corbus Pharmaceuticals não possui acordos ativos de licenciamento de medicamentos gerando receita. O pipeline da empresa permanece em estágios pré-comerciais.

Bolsas de pesquisa e financiamento do governo

Fonte de financiamento	Quantia	Ano
Grant National Institutes of Health (NIH)	US $ 1,2 milhão	2023
Grant de pesquisa em pequenas empresas (SBIR)	$750,000	2023

Parcerias de pesquisa colaborativa

As parcerias de pesquisa colaborativa atuais incluem:

• Instituições de pesquisa acadêmica
• Organizações de pesquisa contratada

Vendas potenciais de produtos farmacêuticos

Não há vendas atuais de produtos farmacêuticos a partir de 2024. O pipeline de produtos permanece em estágios de desenvolvimento.

Monetização da propriedade intelectual

Categoria de patentes	Número de patentes	Valor potencial
Doenças inflamatórias raras	7 patentes	Não revelado
Doenças fibróticas	5 patentes	Não revelado

Receita total da Corbus Pharmaceuticals em 2023: US $ 3,95 milhões (principalmente de subsídios de pesquisa)

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Value Propositions

The core value propositions for Corbus Pharmaceuticals Holdings, Inc. (CRBP) center on delivering differentiated, next-generation therapeutics across oncology and obesity, targeting high unmet medical needs with promising clinical data as of late 2025.

CRB-701: Next-generation Nectin-4 ADC with a favorable safety profile and high Objective Response Rates (ORR) up to 55.6% in mUC.

CRB-701, a next-generation antibody drug conjugate (ADC) targeting Nectin-4, utilizes a site-specific, cleavable linker and a precise drug antibody ratio (DAR) of 2 using monomethyl auristatin E (MMAE) as the payload. Data presented at ESMO 2025, based on a September 1, 2025 data cut, showed encouraging efficacy across several tumor types in heavily pretreated patients (median of 3 prior lines of therapy).

The Objective Response Rates (ORR) observed for the 3.6 mg/kg dose were:

Indication	Objective Response Rate (ORR)
Metastatic Urothelial Carcinoma (mUC)	55.6%
Head and Neck Squamous Cell Carcinoma (HNSCC)	47.6%
Cervical Cancer	37.5%

The safety profile appears favorable, with no Grade 4 or 5 treatment-related adverse events reported. The rate of peripheral neuropathy was low at 8.4% (all Grade 1 or 2), and the discontinuation rate related to CRB-701 was only 6.0%. Registrational studies are planned to start by mid-2026.

CRB-913: Highly peripherally restricted CB1 inverse agonist to address obesity with potentially fewer CNS side effects.

CRB-913 offers a value proposition by aiming to overcome the neuropsychiatric adverse event risks that stopped previous CB1 inverse agonists. Pre-clinical data demonstrated that CRB-913 is markedly more peripherally restricted, with a brain-to-plasma ratio 50 times lower than rimonabant and being 15 times more peripherally restricted than monlunabant. The Phase 1 Single Ascending Dose (SAD) portion showed no treatment-related neuropsychiatric events. The company expected to complete the SAD/Multiple Ascending Dose (MAD) study in Q3 2025 and initiate a Phase 1b study in obese patients in Q4 2025.

CRB-601: Novel anti-αvβ8 integrin monoclonal antibody targeting the tumor microenvironment.

CRB-601 targets the integrin αvβ8 to block the activation of latent TGFβ, which helps restore the body's immune response against cancer cells and may enhance immunotherapies. The dose escalation study was on schedule for completion in Q4 2025.

Potential to treat cancers with high unmet need, like HNSCC and cervical cancer (Fast Track status).

The regulatory pathway is expedited for CRB-701 in indications with high unmet need, providing a faster path to potential market access. The value here is speed to market for patients with few options. The FDA granted Fast Track designation for:

• CRB-701 for recurrent or metastatic HNSCC (September 2025).
• CRB-701 for relapsed/refractory metastatic cervical cancer (December 2024).

Financially, Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $23.3 million for the three months ended September 30, 2025. However, following a $75 million public offering, the company believes its cash position is strong enough to fund operations into 2028.

Finance: draft 13-week cash view by Friday.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so your relationships with regulators, the medical community, and investors are everything right now. These groups are your primary customers in this pre-revenue, clinical-stage environment.

High-touch, direct engagement with regulatory agencies like the FDA for Fast Track programs.

Corbus Pharmaceuticals Holdings, Inc. maintains close, direct engagement with the U.S. Food and Drug Administration (FDA), evidenced by the successful attainment of the Fast Track designation for CRB-701 in two separate indications. This designation is crucial for streamlining development and review for serious conditions. The first was granted in December 2024 for relapsed or refractory metastatic cervical cancer, and the second was granted on September 16, 2025, for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy.

Scientific communication via presentations at major medical conferences (e.g., ESMO 2025) to build credibility.

Building scientific credibility relies heavily on presenting data at top-tier medical forums. Corbus Pharmaceuticals Holdings, Inc. presented updated data from its CRB-701 Phase 1/2 clinical study at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on October 19, 2025. The company also hosted an in-person and virtual HNSCC Key Opinion Leader (KOL) event on the same day, October 19, 2025, starting at 10AM CEST, featuring experts from the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute.

The data presented at ESMO 2025 highlighted efficacy for the 3.6 mg/kg dose:

Tumor Type	Objective Response Rate (ORR)	Disease Control Rate (DCR)
HNSCC	47.6%	61.9%
Cervical Cancer	37.5%	Not explicitly stated for this dose in the same context as HNSCC/mUC
Metastatic Urothelial (mUC)	55.6%	Not explicitly stated for this dose in the same context as HNSCC/mUC

The presentation included data from 167 enrolled participants as of a September 1, 2025, data cut, with 122 evaluable for efficacy.

Close collaboration with clinical investigators and trial sites.

The CRB-701 Phase 1/2 clinical trial (NCT06265727) is a multi-center study conducted across the U.S. and Europe. The trial enrolled patients who were heavily pretreated, with a median of 3 prior lines of therapy (range: 1-9). The company expressed being very pleased with the strong rate of enrollment, which included over 100 participants from the U.S. and Europe by August 2025.

• Dose optimization was on-going at 2.7 mg/kg and 3.6 mg/kg cohorts.
• The study included 41 HNSCC patients, 37 cervical cancer patients, and 23 mUC patients.
• The company planned to meet with the FDA to review data and initiate registrational studies by mid-2026.

Investor Relations (IR) to maintain confidence during the pre-revenue, high-burn clinical stage.

Investor confidence is managed through consistent updates on financing and clinical milestones. Corbus Pharmaceuticals Holdings, Inc. reported Q3 2025 financial results on November 12, 2025. As of September 30, 2025, the company held $104.0 million in cash, cash equivalents, and investment. Following this, they raised $73.8 million in net proceeds from a public offering and ATM sales, leading management to believe they have sufficient cash to fund operations into 2028. Institutional ownership stood at 73.94% as of late 2025. Management actively engaged with the investment community, participating in conferences such as Guggenheim's Second Annual Healthcare Innovation Conference on November 12, 2025 (presentation at 1:00pm ET) and the Jefferies Global Healthcare Conference on November 18, 2025 (presentation at 4:00pm GMT).

The company's financial structure shows minimal leverage, with a debt-to-equity ratio of 0.02, but also reflects the clinical stage with a negative return on equity of -44.13%.

Finance: draft 13-week cash view by Friday.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Channels

Global clinical trial sites for drug testing and data generation utilize the Phase 1/2 study (NCT06265727) for CRB-701, which is being conducted in the U.S. and Europe. The CRB-601 Phase 1 study is also being conducted in the U.S. and Europe.

Data presented at the European Society for Medical Oncology (ESMO) Congress in October 2025 included data from over 100 participants from the U.S. and Europe for the CRB-701 program. The September 1st, 2025 data cut for CRB-701 involved 167 enrolled participants, with 122 participants evaluable for efficacy.

Program	Dose Level	Evaluable Patients (n)	Geographic Scope
CRB-701	3.6 mg/kg	41 (HNSCC)	U.S. and Europe
CRB-701	3.6 mg/kg	37 (Cervical Cancer)	U.S. and Europe
CRB-701	3.6 mg/kg	23 (Metastatic Urothelial Tumors)	U.S. and Europe
CRB-701	Dose Escalation Cohorts	21 (Other Tumor Types)	U.S. and Europe

Direct communication with regulatory bodies focuses on the CRB-701 program, which has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for relapsed or refractory metastatic cervical cancer. Corbus Pharmaceuticals Holdings, Inc. plans an FDA meeting in Q1 2026.

Future pharmaceutical distribution networks are supported by the Company's financial position, which is expected to fund operations through Q2 2027 based on planned expenditures as of June 30, 2025, when cash, cash equivalents, and investment on hand totaled $116.6 million. Following a public offering that raised net proceeds of approximately $73.8M, the cash on hand as of September 30, 2025, was reported at $104.0M.

Investor conferences and press releases are used to communicate milestones, such as the Q2 2025 financial results reported on August 05, 2025 and the Q3 2025 results reported on November 12, 2025. The Company participated in the following events in late 2025:

• Guggenheim Healthcare Innovation Conference: November 12, 2025 at 1:00pm ET.
• Jefferies Global Healthcare Conference: November 18, 2025 at 4:00pm GMT.
• Evercore 8th Annual Healthcare Conference: December 2, 2025 at 3:50pm ET.

The CRB-701 Phase 1/2 dose expansion data was presented as a poster (#967P) at the European Society for Medical Oncology (ESMO) Congress on October 19, 2025 from 12:00-12:45 CEST.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Customer Segments

Patients with Nectin-4 expressing solid tumors, including Head and Neck Squamous Cell Carcinoma (HNSCC) and metastatic Urothelial Carcinoma (mUC).

The CRB-701 Phase 1/2 study (NCT06265727) is designed to enroll approximately 348 patients with advanced solid tumors expressing Nectin-4 who have progressed after at least 1 prior therapy. As of September 1, 2025, the study had 167 enrolled participants, with 122 evaluable for efficacy. The patient population evaluated for efficacy included 41 HNSCC, 23 mUC, and 37 cervical cancer patients. Patients were heavily pretreated with a median of 3 prior lines of therapy.

Tumor Type (Nectin-4 expressing)	Evaluable Patients (as of 9/1/2025)	Objective Response Rate (ORR) at 3.6 mg/kg	Disease Control Rate (DCR) at 2.7 mg/kg
Head and Neck Squamous Cell Carcinoma (HNSCC)	41	47.6%	75.0%
Metastatic Urothelial Carcinoma (mUC)	23	55.6%	N/A
Cervical Cancer	37	37.5%	N/A

Historical market projections for related indications include the global urothelial carcinoma market reaching $6.82 billion in 2032 and the global cervical cancer treatment market reaching $12.63 billion by 2030.

Obese, non-diabetic patients for the CRB-913 program.

Development for CRB-913 is advancing toward a Phase 1b dose-ranging study in obese individuals, planned to commence in the fourth quarter of 2025. The preceding Phase 1 SAD/MAD study is expected to complete in the third quarter of 2025. Pre-clinical data indicated CRB-913 has a brain-to-plasma ratio fifty times lower than rimonabant and is fifteen times more peripherally restricted than monlunabant.

Oncologists and healthcare providers specializing in late-line cancer treatments.

The CRB-701 clinical trial is multi-center and being conducted in the U.S. and Europe. Key Opinion Leaders (KOLs) from institutions including the University of Chicago, Dana-Farber Cancer Institute, and Sarah Cannon Research Institute participated in a KOL event during ESMO 2025. The Company reported a net loss of approximately $23.3 million for the three months ended September 30, 2025.

Global pharmaceutical companies for potential regional licensing or acquisition.

Corbus Pharmaceuticals Holdings, Inc. completed a public offering in October 2025, with a total size of approximately $75 million, before expenses. As of September 30, 2025, the Company had $104.0 million in cash, cash equivalents, and investment on hand, which was extended into 2028 following the offering.

• The Company reported a net loss per basic and diluted share of $1.90 for the three months ended September 30, 2025.
• Operating expenses for the three months ended September 30, 2025, were approximately $24.4 million.
• The Company is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Corbus Pharmaceuticals Holdings, Inc.'s operations as they push their pipeline through late-stage trials. For a clinical-stage biotech, the cost structure is dominated by science and trials, plain and simple.

The most immediate financial impact you see is the bottom line. Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $23.3 million for the three months ended September 30, 2025. This loss reflects the substantial investment required to advance their drug candidates, CRB-701, CRB-913, and CRB-601.

The overall operating expenses for the third quarter of 2025 were approximately $24.4 million, which was an increase of $8.9 million compared to the same period in 2024. This jump is almost entirely attributable to the escalating clinical development expenses across the portfolio.

Here's a look at the cost components, using the more detailed figures available from the second quarter of 2025 to illustrate the relative weight of these categories, remembering that R&D is the clear cost leader:

Cost Category	Q2 2025 Expense (in thousands)	Q2 2025 Expense (USD)	Primary Driver/Example
Research and Development (R&D)	15,187	$15.19 million	Clinical trial costs for CRB-701, CRB-913, and CRB-601 programs
General and Administrative (G&A)	3,965	$3.97 million	Executive compensation, finance, legal, and public company compliance
Total Operating Expenses	19,152	$19.15 million	Sum of R&D and G&A for Q2 2025

Clinical trial costs are the engine of that R&D spend. You're paying for everything that keeps the trials moving forward. It's defintely not cheap.

• Site payments to hospitals and clinics running the studies for CRB-701, CRB-913, and CRB-601.
• Drug supply manufacturing and logistics for the investigational products.
• Patient monitoring, data collection, and statistical analysis services provided by Contract Research Organizations (CROs).
• Costs associated with the CRB-701 combination arm dosing with pembrolizumab.

Manufacturing costs are embedded within R&D, especially for the Antibody Drug Conjugate (ADC) programs. For CRB-701, this involves the complex production of the drug itself, which targets Nectin-4 and uses monomethyl auristatin E (MMAE) as the payload, requiring precise conjugation at a specific drug-to-antibody ratio of 2.

General and Administrative (G&A) costs are the necessary overhead to remain a public entity and manage the business. While smaller than R&D, they are still significant, totaling nearly $4 million in Q2 2025.

• Executive and corporate team salaries, including the CEO, Dr. Yuval Cohen.
• Costs related to SEC filings, investor relations, and maintaining NASDAQ listing compliance.
• Legal fees for intellectual property protection and corporate governance.

To manage this high-burn rate, Corbus Pharmaceuticals Holdings, Inc. completed a $75 million public offering in November 2025, which they believe extends their cash runway into 2028. Finance: draft 13-week cash view by Friday.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) - Canvas Business Model: Revenue Streams

You're looking at a company whose revenue model right now is almost entirely dependent on capital markets, which is typical for a clinical-stage biotech firm. As of late 2025, Corbus Pharmaceuticals Holdings, Inc. has $0K in product revenue because they are still deep in development. To be fair, their Q3 2025 financial results showed a net loss of approximately $23.3 million, which tells you exactly where the money is going: research and trials, not sales. That net loss is up from $13.8 million in the same period last year, showing the burn rate is increasing as they push programs forward.

The primary way Corbus Pharmaceuticals Holdings, Inc. funds these operations is through equity financing. Most recently, they completed a significant underwritten public offering in November 2025, raising approximately $75 million before expenses. This capital raise was crucial; the company stated this infusion extends their cash runway into 2028, giving them plenty of time to hit value-inflection points. For context, their cash position was $116.6 million as of June 30, 2025, and was projected to fund operations through Q2 2027. This new financing definitely helps shore up that runway. Honestly, this is the lifeblood for a company without product sales.

Here's a quick look at the funding and potential future value drivers:

• Recent Equity Raise Amount: $75 million
• Projected Cash Runway Extension: Into 2028
• Q3 2025 Net Loss: $23.3 million
• CRB-701 FDA Status: Fast Track for cervical cancer

Beyond equity, the next major potential revenue stream is tied to the existing partnership with CSPC Pharmaceutical Group for CRB-701, their Nectin-4 targeting Antibody Drug Conjugate (ADC). This deal is structured with significant contingent payments. CSPC is eligible to receive up to $130 million in potential development and regulatory milestone payments. Plus, there's a substantial upside from commercial success, with up to $555 million in potential commercial milestone payments. The total deal value, excluding royalties on net sales, is structured to reach $692.5 million.

Future revenue from product sales is the ultimate goal, driven by the three main pipeline assets. You need to watch the data readouts closely, as positive results are what trigger those milestone payments and attract future investment. CRB-701 showed an Objective Response Rate (ORR) of 47.6% in Head and Neck Squamous Cell Carcinoma (HNSCC) at the 3.6 mg/kg dose, and they are planning a registrational study for HNSCC starting mid-2026. For the obesity candidate, CRB-913, they expected to complete the SAD/MAD study and initiate a Phase 1b study in obese patients by the end of 2025. CRB-601 dose escalation data was also anticipated in Q4 2025. These clinical achievements are the precursors to any future product sales revenue.

Here is a breakdown of the potential future revenue components:

Revenue Source Category	Asset/Event	Potential Financial Amount (USD)	Status/Timeline
Equity Financing (Current Funding)	Public Offering (Completed Nov 2025)	$75 million	Secured; funds operations into 2028
Partnership Milestones (CSPC/CRB-701)	Development & Regulatory Milestones	Up to $130 million	Contingent on clinical/regulatory success
Partnership Milestones (CSPC/CRB-701)	Commercial Milestones	Up to $555 million	Contingent on product sales
Future Product Sales	CRB-701 (Oncology)	Royalties on Net Sales	Registrational study planned mid-2026
Future Product Sales	CRB-913 (Obesity)	Potential Sales Revenue	Phase 1b study expected Q4 2025

The immediate revenue stream is non-existent, relying on the $75 million capital raise to fund the path to potential product sales. Finance: draft 13-week cash view by Friday.